New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 8, 2013
15:37 EDTCELG, ONXXFDA announces approval of Celgene multiple myeloma treatment
The FDA said it approved Celgene's (CELG) Pomalyst to treat patients with multiple myeloma whose disease progressed after being treated with other cancer drugs. In July 2012, the FDA approved Kyprolis to treat multiple myeloma. The FDA said that similar to Onyx Pharmaceuticals' (ONXX) Kyprolis, Pomalyst is being approved under the agency’s accelerated approval program, which provides patients earlier access to promising new drugs while the company conducts additional studies to confirm the drug’s clinical benefit and safe use. The therapy was also granted orphan product designation because it is intended to treat a rare disease or condition. Pomalyst carries a Boxed Warning alerting patients and health care professionals that the drug should not be used in pregnant women because it can cause severe life-threatening birth defects, and that the drug can cause blood clots. Because of Pomalyst’s embryo-fetal risk, it is available only through the Pomalyst Risk Evaluation and Mitigation Strategy Program.
News For CELG;ONXX From The Last 14 Days
Check below for free stories on CELG;ONXX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 15, 2014
07:27 EDTCELGIBC Life Sciences to hold a conference
Subscribe for More Information
September 9, 2014
07:51 EDTCELGNICE says Abraxane price not justified by limited benefit in pancreatic cancer
Subscribe for More Information
September 8, 2014
07:26 EDTCELGMorgan Stanley to hold a conference
Subscribe for More Information
September 5, 2014
10:05 EDTCELGOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Actavis (ACT) initiated with a Buy at ISI Group... Akamai (AKAM) initiated with a Buy at UBS... Alexion (ALXN) initiated with a Buy at SunTrust... Allegion (ALLE) initiated with a Buy at Buckingham... Allergan (AGN) initiated with a Buy at ISI Group... Aviat Networks (AVNW) initiated with a Neutral at H.C. Wainwright... Celgene (CELG) initiated with a Buy at SunTrust... EZCORP (EZPW) initiated with a Hold at Jefferies... Eaton (ETN) initiated with a Neutral at Buckingham... Emerson (EMR) initiated with a Neutral at Buckingham... HMS Holdings (HMSY) initiated with an Overweight at Stephens... Incyte (INCY) initiated with a Buy at SunTrust... Ingersoll-Rand (IR) initiated with a Neutral at Buckingham... Insmed (INSM) initiated with an Outperform at Cowen... Intercept (ICPT) initiated with an Outperform at Cowen... Johnson & Johnson (JNJ) initiated with an Outperform at BMO Capital... Lennox (LII) initiated with a Neutral at Buckingham... Mylan (MYL) initiated with a Hold at ISI Group... Orion Engineered Carbons (OEC) initiated with a Buy at Goldman... Parker-Hannifin (PH) initiated with a Buy at Buckingham... Pentair (PNR) initiated with a Neutral at Buckingham... Pharmacyclics (PCYC) initiated with a Neutral at SunTrust... Rockwell Automation (ROK) initiated with a Neutral at Buckingham... Sabre (SABR) initiated with an Outperform at Oppenheimer... Santander Consumer (SC) initiated with a Buy at Jefferies... Springleaf (LEAF) initiated with a Buy at Jefferies... Susser Petroleum (SUSP) initiated with a Neutral at Credit Suisse... Teva (TEVA) initiated with a Buy at ISI Group... Valeant (VRX) initiated with a Buy at ISI Group... WESCO (WCC) initiated with a Neutral at Buckingham... Watsco (WSO) initiated with a Neutral at Buckingham... Weyerhaeuser (WY) initiated with a Neutral at JPMorgan... World Acceptance (WRLD) initiated with a Hold at Jefferies.
September 4, 2014
17:56 EDTCELGCelgene initiated with a Buy at SunTrust
Target $121.
07:33 EDTCELGCelgene announces REVLIMID Phase III FIRST trial met primary endpoint
Subscribe for More Information
September 2, 2014
09:41 EDTCELGActive equity options trading on open
Subscribe for More Information
08:19 EDTCELGCelgene GED301 drug has positive risk/reward ratio in near-term, says Bernstein
Bernstein believes that the upcoming trial of Celgene's GED0301 drug for Crohn's disease has very little risk in the near-term, while the presentation of results of a study of the drug next month should be positive for the stock. The firm thinks that the drug could emerge as a popular combination partner for other systemic drugs in patients who continue to have disease symptoms. Bernstein is more cautious about the drug's outlook starting in 2016 but keeps a $103 price target and Outperform rating on the stock.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use